Atlas Trials

Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma

Clinical trial NCT05076786 · UNKNOWN

Trial details

NCT number
NCT05076786
Sponsor
Peking Union Medical College Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Neuroendocrine TumorsNeuroendocrine Carcinoma
Start date
2021-10-27
Primary completion
2022-10-15
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.